Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
4,089 JPY -0.02% Intraday chart for Takeda Pharmaceutical Company Limited +0.49% +0.86%
Apr. 26 EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
Apr. 26 Hutchmed notes CHMP's positive opinion for fruiquintinib approval AN

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • One of the major weak points of the company is its financial situation.
  • With an expected P/E ratio at 46.4 and 27.61 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
+0.86% 40.76B
B+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. Ratings Takeda Pharmaceutical Company Limited